DE69835761D1 - Verfahren zum verabreichen von pharmazeutischen präparaten und nukleinsäuren an den skelettmuskel - Google Patents

Verfahren zum verabreichen von pharmazeutischen präparaten und nukleinsäuren an den skelettmuskel

Info

Publication number
DE69835761D1
DE69835761D1 DE69835761T DE69835761T DE69835761D1 DE 69835761 D1 DE69835761 D1 DE 69835761D1 DE 69835761 T DE69835761 T DE 69835761T DE 69835761 T DE69835761 T DE 69835761T DE 69835761 D1 DE69835761 D1 DE 69835761D1
Authority
DE
Germany
Prior art keywords
muscle
nucleic acids
administration
pharmaceutical preparations
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69835761T
Other languages
English (en)
Other versions
DE69835761T2 (de
Inventor
Iacob Mathiesen
Terje Lomo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inovio AS
Original Assignee
Inovio AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inovio AS filed Critical Inovio AS
Application granted granted Critical
Publication of DE69835761D1 publication Critical patent/DE69835761D1/de
Publication of DE69835761T2 publication Critical patent/DE69835761T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/20Applying electric currents by contact electrodes continuous direct currents
    • A61N1/205Applying electric currents by contact electrodes continuous direct currents for promoting a biological process
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36014External stimulators, e.g. with patch electrodes
    • A61N1/36017External stimulators, e.g. with patch electrodes with leads or electrodes penetrating the skin
DE69835761T 1997-04-03 1998-04-03 Verfahren zum verabreichen von pharmazeutischen präparaten und nukleinsäuren an den skelettmuskel Expired - Lifetime DE69835761T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4259497P 1997-04-03 1997-04-03
US42594P 1997-04-03
PCT/IB1998/000487 WO1998043702A2 (en) 1997-04-03 1998-04-03 Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle

Publications (2)

Publication Number Publication Date
DE69835761D1 true DE69835761D1 (de) 2006-10-12
DE69835761T2 DE69835761T2 (de) 2007-09-13

Family

ID=21922760

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69835761T Expired - Lifetime DE69835761T2 (de) 1997-04-03 1998-04-03 Verfahren zum verabreichen von pharmazeutischen präparaten und nukleinsäuren an den skelettmuskel

Country Status (16)

Country Link
US (1) US6110161A (de)
EP (1) EP1023107B1 (de)
JP (2) JP2001520537A (de)
KR (1) KR100427786B1 (de)
CN (1) CN1198665C (de)
AT (1) ATE337794T1 (de)
AU (1) AU733628B2 (de)
CA (1) CA2285056C (de)
DE (1) DE69835761T2 (de)
DK (1) DK1023107T3 (de)
EA (1) EA002087B1 (de)
ES (1) ES2273408T3 (de)
IL (1) IL132103A0 (de)
NO (1) NO327806B1 (de)
NZ (1) NZ337853A (de)
WO (1) WO1998043702A2 (de)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702359A (en) * 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5993434A (en) * 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US6261281B1 (en) * 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
CN1261808A (zh) * 1997-06-30 2000-08-02 罗纳-布朗克罗莱尔股份有限公司 向多细胞真核生物的细胞中转移核酸的改进方法和用于实施该方法的组合
JP2002507985A (ja) * 1997-06-30 2002-03-12 ローヌ−プーラン・ロレ・エス・アー 横紋筋に核酸を導入する改良法およびその組合せ
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US20040229363A1 (en) * 1998-06-24 2004-11-18 Ed Nolan High efficiency transfection based on low electric field strength, long pulse length
US7922709B2 (en) 1998-07-13 2011-04-12 Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
US6678556B1 (en) 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
EP2428249B1 (de) 1998-07-13 2015-10-07 Inovio Pharmaceuticals, Inc. Haut- und muskelgerichtete Gentherapie mithilfe eines gepulsten elektrischen Felds
AU2868200A (en) * 1999-02-08 2000-08-25 Chiron Corporation Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo
US6593130B1 (en) * 1999-04-16 2003-07-15 The Regents Of The University Of California Method and apparatus for ex vivo and in vivo cellular electroporation of gene protein or drug therapy
CA2401239A1 (en) * 2000-03-03 2001-09-13 Valentis, Inc. Improved poloxamer and poloxamine compositions for nucleic acid delivery
AU2001264759B2 (en) 2000-05-22 2006-06-01 Merck & Co., Inc. System and method for assessing the performance of a pharmaceutical agent delivery system
US6733485B1 (en) 2001-05-25 2004-05-11 Advanced Bionics Corporation Microstimulator-based electrochemotherapy methods and systems
US20040204669A1 (en) * 2001-07-05 2004-10-14 Hofmann Gunter A. Apparatus for electroporation mediated delivery for drugs and genes
US7713740B2 (en) * 2001-08-24 2010-05-11 University Of South Florida Method of using electric fields to facilitate the entry of molecules into cells in vivo
DK1436397T3 (da) 2001-10-11 2010-08-09 Merck Sharp & Dohme Hepatitis C virus vaccine
ES2344253T3 (es) 2001-10-11 2010-08-23 MERCK SHARP & DOHME CORP. Vacuna contra el virus de la hepatitis c.
IL161862A0 (en) * 2001-11-08 2005-11-20 Univ California Methods and compositions for correction of cardiac conduction disturbances
EP1474153A4 (de) * 2001-12-14 2005-12-14 Genetronics Inc Verfahren zur partikelunterstützten polynukleotidimmunisierung mit einem gepulsten elektrischen feld
EP1470161A1 (de) * 2002-01-18 2004-10-27 Inovio AS Bispezifische antikörper-dna-konstrukte für die intramuskuläre verabreichung
US20050154434A1 (en) 2002-03-07 2005-07-14 Adam Simon Clinical syringe with electrical stimulation aspects
US7245963B2 (en) * 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
JP4499427B2 (ja) 2002-04-16 2010-07-07 サイト パルス サイエンシズ、インコーポレイテッド 電場の移動及び電極極性の反転で生体材料を処理する方法。
US20040106896A1 (en) * 2002-11-29 2004-06-03 The Regents Of The University Of California System and method for forming a non-ablative cardiac conduction block
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
JP5221127B2 (ja) 2004-03-08 2013-06-26 アイコアー メディカル システムズ、インク. 電気を利用した治療剤移送のための改良された装置
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
EP1865969A4 (de) * 2005-03-19 2009-07-15 Univ California Ultraschwach elektrofeldnetz-vermittelte ex vivo gen-, protein- und arzneiabgabe in zellen
CA2610919C (en) 2005-06-17 2013-09-10 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis c virus nucleic acid vaccine
EP1984007B1 (de) * 2006-02-13 2015-08-19 Oncolytics Biotech Inc. Verwendung von niedrigdosiertem lokaler immunsuppression zur verstärkung einer onkolytischen viralen therapie
KR20090080941A (ko) 2006-11-17 2009-07-27 제네트로닉스, 인코포레이티드 전기천공법을 이용한 백신접종 및 부스팅을 사용하여 면역 반응을 강화시키는 방법들
KR101383476B1 (ko) 2007-11-01 2014-04-11 아스테라스 세이야쿠 가부시키가이샤 면역억제 폴리펩티드 및 핵산
CN107083391A (zh) * 2008-04-04 2017-08-22 宾夕法尼亚大学托管会 屈曲病毒蛋白共有序列、编码该屈曲病毒蛋白共有序列的核酸分子和组合物及其使用方法
JP5873717B2 (ja) 2008-04-04 2016-03-01 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Il−28及び組成物を用いたワクチン及び免疫治療薬並びにその使用方法
EP2147697A1 (de) 2008-07-21 2010-01-27 Centre National De La Recherche Scientifique-CNRS Verfahren und Vorrichtung zur Anwendung elektrischer Felder in leitfähiges Material
EP2156860A1 (de) 2008-08-20 2010-02-24 Centre National De La Recherche Scientifique-CNRS Verfahren zur Herstellung isolierter Elektroden zum Einfügen elektrischer Felder in ein leitfähiges Material
US20100298697A1 (en) * 2009-05-19 2010-11-25 Medtronic, Inc. Method and devices for improved efficiency of rna delivery to cells
US8207138B2 (en) 2009-05-19 2012-06-26 Medtronic, Inc. Methods and devices for improved efficiency of RNA delivery to cells
US8624011B2 (en) 2009-09-14 2014-01-07 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same
CA3177356A1 (en) 2009-11-02 2011-05-05 The Trustees Of The University Of Pennsylvania Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
EP2539354B1 (de) 2010-02-08 2017-04-05 The Trustees Of The University Of Pennsylvania Für rantes kodierende nukleinsäuremoleküle sowie zusammensetzungen und verfahren damit
CA2812789A1 (en) 2010-09-27 2012-04-12 The Trustees Of The University Of Pennsylvania Consensus antigen constructs and vaccines made therefrom, and methods of using same to treat malaria
BR112013011705B1 (pt) 2010-11-12 2022-04-05 The Trustees Of The University Of Pennsylvania Antígenos de próstata de consenso, molécula de ácido nucleico quecodifica os mesmos e vacina e usos compreendendo os mesmos
EA033467B1 (ru) 2011-01-31 2019-10-31 Univ Pennsylvania Молекула нуклеиновой кислоты для индукции иммунного ответа против герпесвируса и ее применение
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
HUE049669T2 (hu) 2011-02-11 2020-10-28 Univ Pennsylvania Hepatitis B vírus magfehérjéjét kódoló nukleinsav-molekula és azt tartalmazó oltóanyag
CA2839196A1 (en) 2011-06-15 2012-12-20 Chrontech Pharma Ab Injection needle and device
ES2758713T3 (es) 2011-07-11 2020-05-06 Inovio Pharmaceuticals Inc Vacuna de ADN contra el virus de Lassa
EP2791362B1 (de) 2011-12-12 2019-07-03 The Trustees Of The University Of Pennsylvania Proteine mit mrsa pbp2a und fragmenten davon, nucleinsäuren zur codierung davon sowie zubereitungen und deren verwendung zur vorbeugung und behandlung von mrsa-infektionen
KR20220132652A (ko) 2011-12-12 2022-09-30 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 il-12 유전적 컨스트럭트 및 백신을 포함하는 조성물, 면역치료제 및 이를 이용하는 방법
WO2013155205A1 (en) 2012-04-10 2013-10-17 The Trustees Of The University Of Pennsylvania Human respiratory syncytial virus concensus antigens, nucleic acid constructs and vaccines made thereform, and methods of using same
EP4190350A1 (de) 2012-04-12 2023-06-07 The Trustees Of The University Of Pennsylvania Filovirus-konsensusantigene, nukleinsäurekonstrukte und daraus hergestellte impfstoffe sowie verfahren zur verwendung davon
DE102012013534B3 (de) 2012-07-05 2013-09-19 Tobias Sokolowski Vorrichtung für repetitive Nervenstimulation zum Abbau von Fettgewebe mittels induktiver Magnetfelder
WO2014064534A2 (en) 2012-10-05 2014-05-01 Chrontech Pharma Ab Injection needle, device, immunogenic compositions and method of use
KR102258021B1 (ko) 2012-12-13 2021-06-01 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Wt1 백신
US11419925B2 (en) 2013-03-15 2022-08-23 The Trustees Of The University Of Pennsylvania Cancer vaccines and methods of treatment using the same
CA2895806C (en) 2013-03-15 2023-02-21 The Trustees Of The University Of Pennsylvania Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
US10272144B2 (en) 2013-07-31 2019-04-30 Bioventures, Llc Compositions for and methods of treating and preventing targeting tumor associated carbohydrate antigens
CN105829341A (zh) 2013-12-13 2016-08-03 宾夕法尼亚大学理事会 Dna抗体构建体及其使用方法
CN114010802A (zh) 2014-12-01 2022-02-08 宾夕法尼亚大学理事会 Dna抗体构建体及其使用方法
US11491342B2 (en) 2015-07-01 2022-11-08 Btl Medical Solutions A.S. Magnetic stimulation methods and devices for therapeutic treatments
US11266850B2 (en) 2015-07-01 2022-03-08 Btl Healthcare Technologies A.S. High power time varying magnetic field therapy
US20180001107A1 (en) 2016-07-01 2018-01-04 Btl Holdings Limited Aesthetic method of biological structure treatment by magnetic field
US10695575B1 (en) 2016-05-10 2020-06-30 Btl Medical Technologies S.R.O. Aesthetic method of biological structure treatment by magnetic field
WO2017055522A1 (en) 2015-09-29 2017-04-06 Academisch Medisch Centrum Stabilized env proteins of hiv
US11253717B2 (en) 2015-10-29 2022-02-22 Btl Healthcare Technologies A.S. Aesthetic method of biological structure treatment by magnetic field
JP7123800B2 (ja) 2016-02-05 2022-08-23 イノビオ ファーマシューティカルズ,インコーポレイティド がんのワクチン及びそれを用いた処置の方法
EA038691B1 (ru) 2016-03-28 2021-10-05 Айкор Медикэл Системс, Инк. Устройство для доставки терапевтических средств
WO2017180770A1 (en) 2016-04-13 2017-10-19 Synthetic Genomics, Inc. Recombinant arterivirus replicon systems and uses thereof
US11247039B2 (en) 2016-05-03 2022-02-15 Btl Healthcare Technologies A.S. Device including RF source of energy and vacuum system
US11464993B2 (en) 2016-05-03 2022-10-11 Btl Healthcare Technologies A.S. Device including RF source of energy and vacuum system
US11534619B2 (en) 2016-05-10 2022-12-27 Btl Medical Solutions A.S. Aesthetic method of biological structure treatment by magnetic field
US10583287B2 (en) 2016-05-23 2020-03-10 Btl Medical Technologies S.R.O. Systems and methods for tissue treatment
US10556122B1 (en) 2016-07-01 2020-02-11 Btl Medical Technologies S.R.O. Aesthetic method of biological structure treatment by magnetic field
CA3040264A1 (en) 2016-10-17 2018-04-26 Synthetic Genomics, Inc. Recombinant virus replicon systems and uses thereof
CN110352247A (zh) 2016-12-05 2019-10-18 杨森制药公司 用于增强基因表达的组合物和方法
WO2019042950A1 (en) 2017-08-26 2019-03-07 Academisch Medisch Centrum IMPROVED HIV ENVELOPE GLYCOPROTETIC IMMUNOGENS
US11235044B2 (en) 2017-12-13 2022-02-01 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting MUC16 and uses thereof
CA3083528C (en) 2017-12-13 2023-09-12 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting mesothelin and uses thereof
BR112020011443A2 (pt) 2017-12-13 2020-12-01 Inovio Pharmaceuticals, Inc. molécula de ácido nucleico e seu uso, vetor e seu uso, composição, proteína e vacina
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
EA202091516A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
EP4272833A3 (de) 2017-12-19 2024-01-10 Janssen Sciences Ireland Unlimited Company Hepatitis b virus (hbv) impfstoff und verwendung
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
WO2019123250A1 (en) 2017-12-19 2019-06-27 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against hepatitis b virus (hbv)
CN111902163B (zh) 2018-01-19 2024-02-13 杨森制药公司 使用重组复制子系统诱导和增强免疫应答
EP3721939B1 (de) 2019-04-11 2022-07-06 BTL Healthcare Technologies a.s. Vorrichtung zur ästhetischen behandlung biologischer strukturen durch hochfrequenz und magnetische energie
WO2020255019A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and a quinazoline derivative
CN114340663A (zh) 2019-06-18 2022-04-12 爱尔兰詹森科学公司 乙型肝炎病毒(HBV)疫苗和靶向HBV的RNAi的组合
EP3986915A1 (de) 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Konstrukt aus rekombinantem interleukin 12 und verwendungen davon
WO2020255018A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Hepatitis b virus (hbv) vaccines and uses thereof
US20220305116A1 (en) 2019-06-18 2022-09-29 Janssen Sciences lreland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being sulfonamide derivatives
WO2020255035A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyrimidine derivatives
WO2020255017A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
US20220241402A1 (en) 2019-06-18 2022-08-04 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
WO2020255013A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being amide derivatives
TW202114731A (zh) 2019-06-18 2021-04-16 愛爾蘭商健生科學愛爾蘭無限公司 B型肝炎病毒(HBV)疫苗與靶向HBV之RNAi之組合
US20220296703A1 (en) 2019-06-18 2022-09-22 Janssen Sciences Ireland Unlimited Company Cobmination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
US20220249647A1 (en) 2019-06-18 2022-08-11 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
US20220233684A1 (en) 2019-06-18 2022-07-28 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pd-l1 inhibitors
WO2020255010A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines
WO2020255038A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
WO2020255022A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and aminopyridine derivatives as hpk1 inhibitors
CA3143634A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
CA3140588A1 (en) 2019-06-18 2020-12-24 Helen Horton Combination of hepatitis b virus (hbv) vaccines and small molecule pdl1 or pd1 inhibitor
WO2020254876A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Virus-like particle delivery of hepatitis b virus (hbv) vaccines
WO2020255042A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and a pyrimidine derivative
WO2020255016A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
AU2020297019A1 (en) 2019-06-20 2022-02-17 Janssen Sciences Ireland Unlimited Company Carbohydrate nanocarrier delivery of hepatitis B virus (HBV) vaccines
EP3986563A1 (de) 2019-06-20 2022-04-27 Janssen Sciences Ireland Unlimited Company Lipidnanopartikel oder liposomenabgabe von hepatitis-b-virus-(hbv)-impfstoffen
US11878167B2 (en) 2020-05-04 2024-01-23 Btl Healthcare Technologies A.S. Device and method for unattended treatment of a patient
KR20230000081U (ko) 2020-05-04 2023-01-10 비티엘 헬쓰케어 테크놀로지스 에이.에스. 환자의 무인 치료를 위한 디바이스 및 방법
CN116133668A (zh) 2020-06-12 2023-05-16 罗切斯特大学 ACE-tRNA的编码和表达
KR20230050328A (ko) 2020-07-08 2023-04-14 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Hbv에 대한 rna 레플리콘 백신
WO2022133230A1 (en) 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
WO2022146654A1 (en) 2020-12-28 2022-07-07 Janssen Pharmaceuticals, Inc. Transcription activator-like effector nucleases (talens) targeting hbv
US11896816B2 (en) 2021-11-03 2024-02-13 Btl Healthcare Technologies A.S. Device and method for unattended treatment of a patient
WO2023150753A1 (en) 2022-02-07 2023-08-10 University Of Rochester Optimized sequences for enhanced trna expression or/and nonsense mutation suppression
WO2023233290A1 (en) 2022-05-31 2023-12-07 Janssen Sciences Ireland Unlimited Company Rnai agents targeting pd-l1

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5389069A (en) * 1988-01-21 1995-02-14 Massachusetts Institute Of Technology Method and apparatus for in vivo electroporation of remote cells and tissue
US5501662A (en) * 1992-05-22 1996-03-26 Genetronics, Inc. Implantable electroporation method and apparatus for drug and gene delivery
US5304120A (en) * 1992-07-01 1994-04-19 Btx Inc. Electroporation method and apparatus for insertion of drugs and genes into endothelial cells
US5273525A (en) * 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5318514A (en) * 1992-08-17 1994-06-07 Btx, Inc. Applicator for the electroporation of drugs and genes into surface cells
US5468223A (en) * 1992-11-30 1995-11-21 C.N.R.S. Paris Electrochemotherapy
FR2703253B1 (fr) * 1993-03-30 1995-06-23 Centre Nat Rech Scient Applicateur d'impulsions electriques pour traitement de tissus biologiques.
US5702359A (en) * 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5993434A (en) * 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
IL108775A (en) * 1994-02-25 2003-09-17 Univ Ramot Method for efficient incorporation of molecules into cells
JPH10502858A (ja) * 1995-05-02 1998-03-17 フィリップス エレクトロニクス エヌ ベー 対象の磁気共鳴画像化方法及び装置
US5944710A (en) * 1996-06-24 1999-08-31 Genetronics, Inc. Electroporation-mediated intravascular delivery
CN1261808A (zh) * 1997-06-30 2000-08-02 罗纳-布朗克罗莱尔股份有限公司 向多细胞真核生物的细胞中转移核酸的改进方法和用于实施该方法的组合

Also Published As

Publication number Publication date
NO327806B1 (no) 2009-09-28
AU6990698A (en) 1998-10-22
CA2285056C (en) 2004-12-14
EA199900882A1 (ru) 2001-02-26
JP2001520537A (ja) 2001-10-30
DE69835761T2 (de) 2007-09-13
AU733628B2 (en) 2001-05-17
CN1198665C (zh) 2005-04-27
NZ337853A (en) 2002-03-28
EA002087B1 (ru) 2001-12-24
KR100427786B1 (ko) 2004-04-30
KR20010005932A (ko) 2001-01-15
NO994820L (no) 1999-12-03
CN1276740A (zh) 2000-12-13
DK1023107T3 (da) 2006-12-27
ES2273408T3 (es) 2007-05-01
US6110161A (en) 2000-08-29
ATE337794T1 (de) 2006-09-15
IL132103A0 (en) 2001-03-19
EP1023107A1 (de) 2000-08-02
JP2006061701A (ja) 2006-03-09
WO1998043702A2 (en) 1998-10-08
NO994820D0 (no) 1999-10-04
EP1023107B1 (de) 2006-08-30
CA2285056A1 (en) 1998-10-08

Similar Documents

Publication Publication Date Title
DE69835761D1 (de) Verfahren zum verabreichen von pharmazeutischen präparaten und nukleinsäuren an den skelettmuskel
Heller et al. Clinical applications of electrochemotherapy
Gratieri et al. Non-invasive iontophoretic delivery of peptides and proteins across the skin
ATE142266T1 (de) Verfahren zum transport von molekülen in eukaryotenzellen
DE69826124D1 (de) Verabreichung der nukleinsäure in den quergestreiften muskel
ATE323169T1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
DE69727958D1 (de) Zusammenstellungen und verfahren zur änderung der bioverteilung von biologischen agentien
EP0552878B1 (de) Moleküle für iontophoretische Verabreichung
DK592186D0 (da) Fremgangsmaade til udvinding af proteiner
ATE209887T1 (de) Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel
DK0559884T3 (da) Rekombinante virusvektorer til ekspression i muskelceller
DE69835228D1 (de) Verfahren zur elektropermeabilisation einzelner zellulärer und organeller strukturen
ATE530659T1 (de) Modulare transfektionssysteme auf der basis von nukleoproteinfilamenten
MA20411A1 (fr) Procede de preparation de polypeptides ayant l'activite du gamma-interferon humain
DE68918279T2 (de) Plasminogenaktivator-varianten und verfahren zu ihrer herstellung.
EE200000102A (et) Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene
IL131436A0 (en) Compositions for treatment of disorders involving programmed cell death
US20010023317A1 (en) Needle with electrodes for electroporation-mediated gene therapy
Zampaglione et al. Genetic vaccination by gene electro-transfer in non-human primates
Haqqi et al. Effect of apholate (ENT 26316; NSC 26812) on nucleic acids, total protein content & activity levels of aminotransferases (GOT, GPT), alkaline phosphatase & 5'-nucleotidase in liver of male albino rats
CN1270225A (zh) Epo基因的电针转移技术
UA13223A (uk) Аhтигельміhтhий препарат та спосіб його одержаhhя

Legal Events

Date Code Title Description
8364 No opposition during term of opposition